Amandeep Gakhal | Director, Protein Engineering
Sutro Biopharma

Amandeep Gakhal, Director, Protein Engineering, Sutro Biopharma

Amandeep leads the Protein Engineering group at Sutro Biopharma.  Her team discovers and engineers proteins to support Sutro’s goal of helping patients by delivering next-generation oncology therapeutics, ranging from antibody drug conjugates to cytokine derivatives.  Amandeep has over 15 years experience working with biologics, including development of ADCs in clinical trials.  She earned a Ph.D. in Immunology from The Scripps Research Institute and completed a postdoctoral fellowship at the University of Toronto.  She also holds a degree in Biochemistry from Simon Fraser University in Vancouver, British Columbia.

Appearances:



Festival of Biologics Day 1 @ 17:30

Discovery of STRO-003, a novel ROR1 targeting ADC using cell free protein synthesis and site-specific conjugation technologies

Sutro's proprietary and integrated cell-free protein synthesis platform and site-specific conjugation platform enables homogeneous ADCs with best-in-class potential. STRO-003 is a ROR1 targeting ADC with a stable β-glucoronidase cleavable linker and TOPO-1 inhibiting exatecan warhead, precisely positioned by non-natural amino acids to enable a drug-antibody ratio of 8. STRO-003 demonstrates potent and ROR1 dependent tumor killing in preclinical models with favorable safety, providing opportunity for treatment of tumors.

last published: 31/Jan/23 09:55 GMT
last published: 31/Jan/23 09:55 GMT

back to speakers